Steve

#AVCT oh nothing to see here. Just AVACTA destroying the income of AstraZeneca’s multi billion pound earning drug that will become the go to for 90% solid tumours in rapid time as it’s known proven drug. Watch the FDA accelerate it to use 28/29

New added to the clinical trials site for #AVCT in Michigan. START Midwest is a new facility group also. Ronan Pleass in charge. You don't do this is AVA6103 is not performing... That is now 3 out of 8 sites for P1A online....more to come here. Science day said 8 would support P1A and up to 20 for the next stage! #version-content-panel" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT07454…

@downunderfutbol Some minor updates to AVA6000 today as well - estimated study completion 15th June #version-content-panel" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT04969… #AVCT

Michigan open for recruitment #avct

@MBdaytrading Let's check to see how it does again tomorrow too!

Anyone else notice #AVCT seems to do very well when the US markets are open !

A nice little reminder of what we hold from our very own CC 🫶🏻 #avct

#AVCT has traded ~24m shares over the last 5 sessions. Today’s conversion represents ~c.6.5% of a 5-day volume. Before Richard Hughes joined AVCT’s board this single exercise could equate to 100% of 3 days’ volume. The CLN is now an irrelevance: <5% of m.cap in unsecured debt.

@BigBiteNow @PJ_Crabb That's exactly how it was put to me after the SD presentation when I broached the CLN with a senior member of the #avct management team. " It's increasingly an insignificant factor and it is well in hand".

business-news-today.com/avacta-group-a… #AVCT

26 Jan 2024. 288m shares in issue. #AVCT had a £288m market cap. No AVA6000 PFS. No FDA dosing limit removal. No AVA6103. No AVA6207. No pipeline. £397m today. Adding ~£110m market cap in ~2.5 years. Or if you prefer ~38%. The S&P is up 55% over this period. The NASDAQ +75%. FTSE100 +30%. The gains, over this period, for holding a first in human novel peptide, are genuinely embarrassing.

@tom_the_bomb__ @avacta Avacta's valuation has certainly been ignored for too long, it's about fricking time some form of reality will now arrive! Bring on the rest of 2026! 💪📈

The last time #AVCT was in the 100s was early 2024. Since then, the progress made by @avacta has been significant. The next 6 months are loaded up with catalysts. The valuation disconnect can't continue to be ignored. C'mon the Avacta ⏰🚀

Rampers are just as bad and clueless as the trolls. #AVCT is manipulated by a huge trading element, with MMs having fun with it. Ignore. SGC data early June + fast track.

Just when you thought that was it you hear about the dual warhead AVA6207 ambitions which will no doubt be crystallising into multiple commercial deals in due course. The optionality is astounding and you don't spend time talking about AVA6207 which uses exatecan and the same warhead being used in the AVA6103 trial unless it is working!! Congratulations to all the team. 4/4

#AVCT “The FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition.” #BiotechStocks #BiotechInvesting #Oncology #OncologyStocks

#AVCT If you’re excited by eighty two pence per share you really don’t understand the technology.

When the SD video is released I would recommend those watching #AVCT or considering an entry pay close attention to the CEO for the first 20 mins on her feet. No notes, fluent as they come, polished and absolutely oozing confidence. She knows exactly what she has. Until 2045.

@coughlin582 didn’t put a foot wrong at yesterday’s event. The company and technology is being propelled forward, at pace, on budget. There was not a doubt in room as to the size of opportunity which sits before #AVCT. That elusive ‘validation’ from Pharma inevitably follows.

#AVCT - Thanks to those who attended the Science Day for posting their views. The fact that Dr. Spira shared his thoughts, the lead investigator for AVA6103 is a massive endorsement for the drug and for the Avacta team.